Categories
Change Password!
Reset Password!
Double-blind placebo-controlled food challenges (DBPCFCs) are generally safe, with severe reactions being rare and previous reaction severity helping predict anaphylaxis.
Oral food challenges, specifically double-blind placebo-controlled food challenges (DBPCFCs), remain the definitive gold standard for diagnosing food allergies. However, clinical apprehensions regarding adverse safety outcomes have historically constrained their widespread adoption in routine outpatient practice. Understanding the true incidence of severe reactions and identifying reliable clinical predictors of risk are critical for optimizing patient selection and risk stratification.
Researchers analyzed data from the EuroPrevall outpatient clinic study, evaluating 514 DBPCFC procedures performed on patients reporting immediate hypersensitivity reactions to common allergenic foods, including milk, egg, fish, shrimp, peanut, hazelnut, celeriac, apple, and/or peach. Individuals with a documented history of prior life-threatening anaphylaxis were systematically excluded.
Reaction severities both patient-reported historical accounts and DBPCFC-elicited responses were assessed using the validated Food Allergy Severity Score. A two-step modeling strategy utilizing generalized estimating equations was implemented to identify predictors of positive challenge outcomes and, among positive cases, specific predictors of anaphylaxis.
Of the 514 challenges executed, 190 (36.9%) yielded negative results, 30 (5.8%) were uncertain, and 294 (57.2%) tested positive. Among the positive challenges, 102 manifested as mild oropharyngeal reactions (19.8%), while 192 resulted in systemic reactions (37.4%).
Breaking down the systemic events further:
Multivariable modeling revealed distinct predictors governing challenge reactivity and severe outcomes:
These findings offer robust reassurance regarding the safety profile of DBPCFCs when executed under proper medical supervision, demonstrating that severe systemic hypotension or life-threatening events are exceedingly rare. By recognizing that atopic dermatitis and specific IgE sensitization identify reactivity risk—while prior reaction history flags anaphylaxis potential—clinicians can refine patient selection and risk stratification in everyday allergy practice.
Journal of Investigational Allergology and Clinical Immunology
Severity of Reactions in Double-Blind Placebo-Controlled Food Challenges: New Insights From the EuroPrevall Outpatient Clinic Study
Rosialzira N Vera-Berrios et al.
Comments (0)